Scantox's Strategic Acquisition of DuplexSeq™ Safety Business Enhances Genomic Testing Capabilities

Scantox's Strategic Acquisition of DuplexSeq™ Nonclinical Genomics Safety Business

Scantox Group, a prominent player in genomic safety testing, has recently made headlines with its acquisition of the DuplexSeq™ nonclinical genomic safety business from TwinStrand Biosciences. This innovative move is set to significantly enhance Scantox’s capabilities in the realm of genetic toxicology, enabling the provision of high-precision mutagenesis testing on a global scale. The acquisition reportedly comes as part of a technology transfer and license agreement, giving Scantox exclusive rights to provide DuplexSeq™ Mutagenesis Assays worldwide.

As development teams in the pharmaceutical industry increasingly face the pressure of regulatory compliance and the need for rapid decision-making on mutagenic risk, the demand for advanced mutagenesis assessment technologies has surged. The DuplexSeq™ technology, known for its use of error-corrected next-generation sequencing, delivers unprecedented accuracy when quantifying ultra-rare mutations. This groundbreaking approach allows researchers to measure mutations directly at the genomic level, providing insights that were previously hard to achieve.

Jeanet Løgsted, the CEO of Scantox Group, expressed her enthusiasm for the acquisition, stating, "Our customers have been asking for access to the most advanced mutagenesis assessment technologies, and this acquisition delivers exactly that." She further highlighted the sensitivity and accuracy of DuplexSeq™, emphasizing its potential to significantly improve the quality of decision-making data available to researchers. With this implementation, Scantox aims to combine its existing Big Blue® transgenic rodent gene mutation assay portfolio with DuplexSeq™ to create a comprehensive genomic safety platform that spans the entire drug development lifecycle.

Chad Waite, Chairman of the Board of Directors at TwinStrand Biosciences, echoed this sentiment. He remarked, "After years of ground-breaking scientific work developing this innovative technology, TwinStrand has found the right home for its genetic safety business in Scantox." He acknowledges Scantox's combination of scientific rigor, quality systems, and extensive regulatory expertise, positioning it well to deliver DuplexSeq to the genetic safety industry at an enhanced scale.

Matt Tate, Scantox's Managing Director of Genetic Toxicology, explained the implications of the DuplexSeq™ technology in clearer terms. He remarked that this new approach allows for more robust decision-making regarding mutagenic risks not just in pharmaceutical development, but also in broader chemical and consumer product programs. This integration signifies a shift towards a more data-driven methodology in genetic toxicology, supporting more informed regulatory submissions.

Moreover, the DuplexSeq’s capabilities extend beyond simple testing; it can serve as an embedded endpoint in wider nonclinical studies, enhancing its applications across various regulatory frameworks concerning carcinogenicity evaluations and gene-editing safety assessments. The possibilities opened by this technology reflect a paradigm shift in how mutagenesis assessments can inform the entire development process, from preclinical phases through to late-stage trials.

As the landscape of genomic safety assessment evolves, Scantox’s acquisition of DuplexSeq™ positions them at the forefront of innovation in genetic toxicology. By marrying state-of-the-art technology with their established expertise, they are poised not only to meet current industry demands but also to set new standards in genomic safety assessment moving forward.

In conclusion, Scantox’s acquisition of DuplexSeq™ represents a strategic advancement in the field of genomic testing. It stands as a testament to the importance of continual innovation in the life sciences and reflects a proactive approach to integrating modern technology into rigorous scientific processes. As this new chapter unfolds, the implications of DuplexSeq’s integration into the broader spectrum of genetic toxicology will be paramount in ensuring safety and compliance in the rapidly advancing pharmaceutical landscape.